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Abstract:  The  intercalation  of  cetirizine  into  two  types  of  layered  double  hydroxides, 
Zn/Al and Mg/Al, has been investigated by the ion exchange method to form CTZAN and 
CTMAN  nanocomposites,  respectively.  The  basal  spacing  of  the  nanocomposites  were 
expanded to 31.9 Å for CTZAN and 31.2 Å for CTMAN, suggesting that cetirizine anion 
was intercalated into Layered double hydroxides (LDHs) and arranged in a tilted bilayer 
fashion. A Fourier transform infrared spectroscopy (FTIR) study supported the formation 
of both the nanocomposites, and the intercalated cetirizine is thermally more stable than its 
counterpart in free state. The loading of cetirizine in the nanocomposite was estimated to 
be  about  57.2%  for  CTZAN  and  60.7%  CTMAN.  The  cetirizine  release  from  the 
nanocomposites  show  sustained  release  manner  and  the  release  rate  of  cetirizine  from 
CTZAN and CTMAN nanocomposites at pH 7.4 is remarkably lower than that at pH 4.8, 
presumably due to the different release mechanism. The inhibition of histamine release 
from RBL2H3 cells by the free cetirizine is higher than the intercalated cetirizine both in 
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CTZAN  and  CTMAN  nanocomposites.  The  viability  in  human  Chang  liver  cells  at  
1000 μg/mL for CTZAN and CTMAN nanocomposites are 74.5 and 91.9%, respectively. 
Keywords:  (Zn/Al,  Mg/Al)-layered  double  hydroxides;  cetirizine;  nanocomposite; 
controlled release; RBL2H3 cell; human Chang liver cells 
 
1. Introduction 
Pharmaceutical science usually suffers from short time release of the active compounds in the body 
to maintain the therapeutic window. Sustained release of drug for more effective delivery systems have 
received intense attention in recent years from the pharmaceutical industry due to the advantages they 
offer over conventional forms [1]. Layered double hydroxide (LDH) is one of the carriers which many 
offer, the benefits of which include prolongation of drug action, a decrease or elimination of side 
effects and enhanced efficiency of drug delivery. LDH has 2-D, positively-charged layers which are 
produced from the isomorphous substitution of magnesium cations by trivalent cations in a brucite 
structure. The brucite structure of the magnesium hydroxide, Mg(OH)2 is composed of magnesium 
cations which are located as centered to six octahedrally hydroxyl groups. Each hydroxide is bonded to 
three magnesium atoms, resulting in neutral layer structure. To neutralize the positive charge of LDH 
structure,  counter  anions  are  intercalated  between  the  interlayers  which  give  the  hydrotalcite-like 
structure with the general formula        O H . A OH M M 2 /
- m
2
3
x
2
x - 1 n m x
x  
, where M
II are divalent cations, 
M
III are trivalent cations and A
m− is an exchangeable anion with charge (m
−) [2]. 
The intercalation of drugs as guest molecules into LDH can be accomplished by different methods; 
the two most common are coprecipitation and ion exchange [3]. Recently, many LDH compounds with 
intercalated  drug  anions  have  been  elucidated,  such  as  the  anticancer  drugs:  methotrexate  [4],  
5-fluorouracil  [5]  and  podophyllotoxin  [6];  the  anti  inflammatory  drugs:  fenbufen,  diclofenac, 
ibuprofen  and  camptothecin  [7–10];  the  anti-hypertensition  drugs:  captopril  [11],  perindopril  
erbumine [12] and ramipril [13]; the antifungal, 5-fluorocytosie [14], and finally the antibiotic drugs, 
gramicidin, amphotericin B, ampicillin and nalidixic acid [15]. 
Antihistamine drugs prevent histamine release by displacement from the receptor. Histamine release 
can  happen  in  the  case  of  tissue  injury  and  allergic  reactions  [16].  Cetirizine  dihydrochloride  
((2-1-piperazinyl ethoxy) acetic acid) is one of a second-generation of antihistamines which can inhibit 
histamine release by blocking the H1 receptor. 
The intercalation of antihistamine into LDH is interesting and, to date, cannot be found in the open 
literature.  Therefore,  in  this  work,  we  discuss  the  intercalation  of  cetirizine  into  Zn/Al-  and  
Mg/Al-LDH. We will concentrate on the spatial orientation of cetirizine moiety between the layers and 
its  release  properties.  In  addition,  we  also  report  here  the  study  of  the  effect  of  the  resulting 
nanocomposites  on  the  histamine  release  from  RBL2H3  cells  as  well  as  their  LDH  counterparts, 
Zn/Al- and Mg/Al-LDH.  Int. J. Mol. Sci. 2012, 13  5901 
 
 
2. Results and Discussion 
2.1. Powder X-Ray Diffraction 
XRD patterns of the nanocomposites demonstrate successful intercalation of cetirizine into both 
fresh Zn/Al- and Mg/Al-LDH hosts (Figure 1A,B, respectively). During ion-exchange nitrate anions, 
the d- spacing of inorganic layers, Zn/Al- and Mg/Al-LDH, which are 9.01 and 8.2 Å, respectively was 
expanded for the host cetirizine anions. This expansion is reflected by the d-spacing values that were 
calculated from the mean values of the first, second, third and fourth order peaks of the XRD patterns, 
which are 31.9, 15.93, 10.64 and 7.88 Å, respectively for CTZAN, and 31.15, 15.33, 10.15 and 7.66 Å, 
respectively for CTMAN. As a result, a basal spacing value of 31.8 Å for CTZAN and 30.8 Å for 
CTMAN  was  obtained.  In  the  case  of  CTZAN,  the  XRD  patterns  show  one  peak  at  
2θ 26°  (d = 9.54 Å), which is overlapping with a peak at 11.22° . This result indicates the presence of 
some un-reacted Zn/Al-NO3-LDH remains in the sample. Previous studies have indicated that it is 
difficult to exchange nitrate in LDHs with the incoming anions, due to the parallel orientation of nitrate 
ions  with  respect  to  the  hydroxide  layers.  As  a  result,  some  nitrate  anions  remained  after  the 
intercalation  process  of  cetirizine  into  Zn/Al  LDH  and  this  explained  why  some  un-reacted  
Zn/Al-NO3-LDH remained [17]. A slight discrepancy in the d003 value between CTZAN and CTMAN 
nanocomposites is probably mainly due to the content of water in the interlayer galleries and the 
presence of nitrate ions in the interlayer region [18]. 
Figure  1.  Powder  X-ray  diffraction  patterns  of  (A)  CTZAN  and  (B)  CTMAN 
nanocomposites. Inset: XRD diffraction for Zn/Al-LDH and Mg/Al-LDH. 
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The lattice parameters, a and c of the PMAE and PZAE nanocomposites are listed in Table 1 and 
were calculated using the d-values of 003, 006 and 009 reflections, where (c = 1/3(3d003 + 6d006 + 
9d009)), and 110 reflection for parameter a, where (a = 2d110). Table 1 shows that the c value for 
CTZAN and CTMAN is 95.5 Å and 92.4 Å, respectively, which suggests that the cetirizine anions 
should be arranged in the interlayer space in a similar fashion, and that the small differences between 
them  can  be  related  to  the  conditions  of  preparation  and/or  more  probably,  the  water  content,  as  
mentioned earlier. 
Table  1.  XRD  data  of  diffraction  peaks  and  the  lattice  parameters  of  CTZAN  and  
CTMAN nanocomposites. 
Samples 
 
d003 
(Å) 
d006 
(Å) 
d009 
(Å) 
d012 
(Å) 
d110 
(Å) 
Average 
d value 
a 
(Å) 
c 
(Å) 
M
2+/Al
3+  x 
CTZAN  31.90  15.93  10.64  7.88  1.51  31.8  3.02  95.5  3.3  0.23 
CTMAN
  31.15  15.33  10.15  7.66  1.51  30.8  3.02  92.4  2.03  0.33 
2.2. Molecular Structure and Spatial Orientation of the Intercalated Cetirizine  
Figure 2A shows the three ionizable forms of cetirizine; a strong acidic group with pK2 = 2.9, a 
strong basic group with pK3 = 8.0 and a very weakly basic group with pK1 = 2.2 [19]. According to 
XRD  analysis,  the  d  spacing  (d003)  increased  to  31.8  Å  and  30.8  Å  for  CTZAN  and  CTMAN, 
respectively. Due to the value of thickness of the Zn/Al and Mg/Al-LDH layers are constant, which is 
4.8 Å [20], thus, the gallery height of LDH after intercalation can be calculated by the d spacing minus 
the thickness of the LDH layer which is 27 Å (31.8–4.8) for CTZAN and 26 Å (30.8–4.8) for CTMAN. 
The long, short axis and thickness of cetirizine anion was calculated using a Chemoffice software 
(Cambridge, MA), and they are 16.2, 8.5 and 11.8 Å, respectively (Figure 2B). The gallery height of 
CTZAN and CTMAN nanocomposites are far beyond the value of the long axis. It is also slightly 
smaller  than  twice  of  the  long  axis  dimension  (32.4  Å).  This  suggests  that  cetirizine  anions  are 
accommodated as alternately tilted bilayer along the long axis orientation in certain angle between 
LDH layers, where the carboxyl anion group attaching to the upper or lower layers, respectively. 
Figure  2.  Modular  structure  of  cetirizine  (A),  three-dimensional  molecular  size  of 
cetirizine (B) and spatial orientation of cetirizine between LDH inorganic interlayers (C). 
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2.3. Fourier Transforms Infrared Spectroscopy 
Figure 3 and Table 2 show FTIR spectra of the cetirizine, CTZAN and CTMAN nanocomposites. 
As shown in Figure 3A for pure cetirizine, a broad band at 3432 cm
−1 is due to the O–H stretching 
vibration [21]. A band recorded at 3044–3023 cm
−1 is due to C–H stretching of the aromatic ring.  
A (C=O) of the carboxylic group gives a strong band at 1740 cm
−1. A band at 1457 cm
−1 is due to C–Cl 
stretching. Mono-substitution on the benzene ring gives three different absorption bands at 1496, 1077 
and 758 cm
−1. Substitution at para position on the benzene ring gives a band at 1602 cm
−1. Bending 
two adjacent benzene rings give bands at 846–809 cm
−1. 
The FTIR spectra of CTZAN and CTMAN nanocomposites are shown in Figure 3B,C, respectively, 
show characteristic bands of cetirizine. This indicates that the cetirizine anions have been intercalated 
into the interlayer galleries of the Zn/Al- and Mg/Al-LDH. However, some of the bands are slightly 
shifted in position, due to interaction between cetirizine anions and the inorganic LDH host interlayers. 
Table 2 shows the FTIR assignments for CTZAN and CTMAN nanocomposites. An intense bands at 
1601 and 1408 cm
–1 of the CTZAN are attributed to asymmetric and symmetric carboxylate stretching 
of the cetirizine anions, respectively. The CTMAN nanocomposite shows bands at 1589 and 1408 cm
–1 
for asymmetric and symmetry stretching, respectively. Peaks at 428 cm
–1 and 446 cm
–1 are associated 
with M-O stretching modes in the CTZAN and CTMAN, respectively [5,22]. 
Figure 3. FTIR spectra of cetirizine (A), CTZAN (B) and CTMAN(C). 
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Table 2. Fourier transform infrared assignment for cetirizine, CTZAN and CTMAN [23,24]. 
Assignments  Cetirizine  CTZAN  CTMAN 
ν (O–H)  3432 for O–H in carboxylic 
group 
3445 in the layer; H2O  3442 
ν (CH2)  2984–2949  2958–2817  2958–2819 
ν (COOH)  1740  -  - 
ν (φ. Para- subst.)  1601  1601  1589 
ν (φ. mono- subst.)  1496, 1077 and 758  1487  1488 
ν (C–Cl)  1457  1452  1453 
ν (C–O) in carboxylic 
group 
1435, 1383, 1356 and 1319  -  - 
2 adj. φ  846 and 809  853 and 805  853 and 805 
ν (CH mono- subst.)  758  758  758 
M-O  -  428  446 
νas (COO
−)  -  1601  1589 
νs (COO
−)  -  1408  1408 
2.4. Elemental Analysis 
Elemental analysis was done for the organic and inorganic composition of CTZAN and CTMAN, as 
shown in Table 3. As expected, the CTZAN and CTMAN nanocomposites contained both organic and 
inorganic constituents. Both elemental analysis and XRD study indicates that intercalation occurred in 
which cetirizine was intercalated into the LDH inorganic interlayers. 
Table 3. Elemental chemical compositional and empirical formula for cetirizine nanocomposites. 
Samples  M
2+% 
a  Al
3+% 
a  C% 
b  N% 
b  C/N  Drug% 
b  Empirical formula 
CTZAN  21.5  2.7  37.2  4.2  8.8  57.2
         O H 16 . 1 . NO CT OH Al Zn 2 01 . 0
-
3 22 . 0 2 0.23 0.77  
CTMAN  8.03  4.37  39.4  4.4  9.04  60.7
       O H 4 . 1 . CT OH Al Mg 2 33 . 0 2 0.33 0.67  
M
2+ is Zn for CTZAN and Mg for CTMAN, 
a calculated upon ICP data; 
b calculated upon CHNS data. 
Table 3 shows that the percentage loading of cetirizine in CTZAN and CTMAN nanocomposites 
are 57.2 and 60.7%, respectively. The C/N ratio for free cetirizine is 9.1 and this value is similar to 
CTMAN nanocomposite, indicating complete removal of the nitrate anion between the interlayer. In 
case of CTZAN, the ratio is less than 9.1; it is about 8.8, which is due to the presence of un-reacted 
ZnAl-NO3.  This  result  was  confirmed  by  the  presence  of  a  very  low  intensity  peak  at  2θ  9.26°   
(d  =  9.54  Å)  in  the  XRD  pattern.  From  the  elemental  chemical  analysis  and  thermogravimetric  
studies,  the  empirical  formula  was  derived  as  shown  in  Table  3  for  both  CTZAN  and  
CTMAN nanocomposites. 
2.5. Thermal Study 
TGA/DTG  thermogravimetric  analyses  obtained  for  cetirizine  hydrochloric  acid,  CTZAN  and 
CTMAN  nanocomposites  are  reported  in  Figure  4.  For  free  cetirizine  (Figure  4A),  the  thermal 
behavior shows that the temperature maxima is at 290
 ° C with weight loss of 90.6% compared to  Int. J. Mol. Sci. 2012, 13  5905 
 
 
350 °C  for the CTZAN and 348 ° C for the CTMAN. This indicates that cetirizine encapsulated into the 
inorganic interlamellae is thermally more stable than their counter part in the free form. It is worth 
mentioning that very small weight loss in Figure 4A started at 159 ° C to 210 ° C is presumably due to 
the evolution of hydrochloric acid [24]; the weight loss for cetirizine is stopped at 900 ° C due to the 
vaporization of the remaining cetirizine material.  
For CTZAN nanocomposite, two stages of weight loss were observed in Figure 4B. The weight 
losses occur at temperature maxima of 165 and 350 ° C with weight losses of 10.6% and 49.3%, 
respectively. The first stage of weight loss is attributed to the removal of surface physisorbed and 
intercalated  water  molecules,  followed  by  the  second  stage  of  weight  loss,  which  is  due  to  the 
decomposition of interlayer cetirizine anion and dehydroxylation of the hydroxyl layer at 350 ° C with 
49.3% weight loss. Similar to free cetirizine, the weight loss in CTZAN nanocomposite stopped at  
999 ° C with 10 % weight loss from 506 to 999 ° C. 
Figure 4. TGA/DTG thermograms of (A) cetirizine, (B) CTZAN and (C) CTMAN. 
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Figure 4C shows the thermal behavior of CTMAN nanocomposite, with two major stages of weight 
loss process occurring at the temperature maxima of 61 and 348 ° C, with weight losses of 12 and 
63.8%, respectively. The first weight loss corresponds to removal of water physisorbed and interlayer 
strongly held  water molecules. The second weight  loss is  complete at 726
 ° C and corresponds to 
removal  of  hydroxyl  groups  from  the  layers  and  the  decomposition  of  the  cetirizine  anions  with  
63.8% weight loss. 
2.6. Surface Characterization 
The surface morphology of Zn/Al-, Mg/Al-LDH, CTZAN and CTMAN nanocomposites are shown 
in  Figure  5.  The  micrographs  were  obtained  using  a  FESEM  (Figure  5A,C,E,G)  at  25,000×   and  
(Figure 5B,D,F,H) at 50,000×  magnifications. Zn/Al-LDH and CTZAN shows non-uniform, irregular 
agglomerates of compact and non-porous plate-like structure (Figure 5A–D). Mg/Al-LDH exhibits a 
plate-like morphology  (Figure 5E,F).  Formation of the nanocomposite,  CTMAN has  resulted in a 
morphology change to agglomerates of compact and non-porous granular structure (Figure 5G,H). 
Figure  5. FESEM microscopic images of  ZnAl-LDH  (A  and B), CTZAN (C and  D), 
MgAl-LDH (E and F) and CTMAN (G and H). 
 
2.7. Release Behavior of Cetirizine 
The release profiles of cetirizine from the CTZAN and CTMAN nanocomposites and the physical 
mixture of cetirizine and the pristine Zn/Al- and Mg/Al-LDH are shown in Figure 6. It can be seen 
from inset of Figure 6I that the physical mixture of cetirizine and pristine LDH exposed to either a pH 
4.8 or 7.4 environment, cetirizine was released quickly; the release was completed within 5 min. The 
release rate of cetirizine from the CTZAN and CTMAN nanocomposites are obviously slower than 
that from the physical mixture as shown in the Figure 6I,II, indicating that both the nanocomposites are 
potential  drug  controlled  release  systems.  This  may  be  attributed  to  the  electrostatic  interaction 
between layers of LDHs and cetirizine anions intercalated into the interlayers. Int. J. Mol. Sci. 2012, 13  5907 
 
 
In  addition,  the  acidity  of  the  media  can  also  affect  the  release  rate  of  cetirizine  from  the 
nanocomposites. The release rate at pH 7.4 is remarkably lower than that at pH 4.8. The percentage 
release of cetirizine from the CTZAN and CTMAN nanocomposites reaches about 95.6 and 96.3% 
within  about  600  and  2980  min,  respectively  when  exposed  to  the  pH  7.4  environment  
(Figure  6A,C);  compared  to  only  about  96  and  97.8%  within  about  600  and  750  min  at  pH  4.8  
(Figure 6B,D), respectively. Such differences in the release rate at pH 4.8 and 7.4 may be possibly due 
to  the  difference  in  mechanism  for  the  release  of  cetirizine  from  the  nanocomposites  [25].  At  
pH 4.8, the LDH is unstable and may be dissolved, thus the release of cetirizine molecules occurs by 
removal of LDHs layer. At pH 7.4, the LDHs should be more stable and the release occurs through a 
diffusion and dissolution of LDHs. 
Figure 6. (I) Release profiles of cetirizine from the CTZAN nanocomposite at pH 7.4 (A) 
and pH 4.8 (B); and (II) release profiles of cetirizine from the CTMAN nanocomposite at 
pH 7.4 (C) and pH 4.8 (D). Inset in (I) shows the release profiles of cetirizine from its 
physical mixture of cetirizine with LDH at pH 7.4 and pH 4.8. 
 
The release rate from CTMAN is obviously very much lower than CTZAN. Completed 96.3% 
release was observed within 2980 min compared to 95.6% within 600 min at pH 7.4. These results are 
due to the charge density in which the charge density, x for CTMAN is 0.33, which is higher than the 
CTZAN, 0.23 (Table 1). Increases in the charge density will lead to the increase in the electrostatic 
interaction between the  positively charged layers  of  LDH lattice  and the interlayer anions that  to  
be released.  
2.8. Release Kinetics of Cetirizine from CTZAN and CTMAN Nanocomposites 
The release behavior of cetirizine from CTZAN and CTMAN nanocomposites can be described by 
different kinetics models, pseudo-first order (Equation (1)) [26], pseudo-second order (Equation (2)) [27] 
and parabolic diffusion (Equation (3)) [28] equations; 
ln (qe − qt) = ln qe − k1t                    (1) 
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t/qt = 1/k2qe
2 + t/qe                                                          (2) 
(1 − Mt/M0)/t = kt
−0.5 + b                                      (3) 
where, M0 and Mt are the drug content remained in the LDH at release time 0 and t, respectively,  
qe and qt are the equilibrium release amount and the release amount at time t, respectively; and k is the 
corresponding release rate constant. 
Figure  7. Fitting the data of cetirizine release from  CTZAN (A and  B) and CTMAN  
(C and D) into pseudo-second order kinetics model at pH 7.4 and 4.8. 
 
With the use of the three kinetic models as mentioned earlier for the release kinetic data; it was 
found  that  the  pseudo-second  order  model  is  more  satisfactory  for  describing  the  release  kinetic 
processes of cetirizine from the nanocomposites compared to the other models used in this work. 
Figure 7 shows the plots of t/qt against t for pseudo-second order kinetic model, and the resulting 
correlation  coefficient  and  the  rate  constant  k2 values  is  given  in  Table  4.  For  the  CTZAN,  the 
correlation coefficient (R
2) and k2 values are 0.9885, 1.07 ×  10
−4 and 0.9985, 3.24 ×  10
−4 at pH 7.4 and 
4.8, respectively. For the CTMAN, the value is 0.9983, 4.14 ×  10
−5 and 0.9914, 1.65 ×  10
−4 at pH 7.4 
and 4.8, respectively. The results of kinetic model obtained in this work are similar to the kinetic study 
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for the release of camptothecin from Mg/Al layered double hydroxide [26] and also very similar to the 
intercalated perindopril erbumine into Zn/Al-layered double hydroxide [12]. 
Table 4. Correlation coefficient (R
2), rate constants (k) and half time (t1/2) obtained by 
fitting the cetirizine release data from CTZAN and CTMAN nanocomposites into solutions 
at pH 4.8 and 7.4. 
Samples  pH 
Saturation 
release (%) 
R
2  Pseudo-second order 
Pseudo-first 
order 
Pseudo-
second order 
Parabolic 
diffusion model 
Rate constant k 
(mg/min) 
t1/2 
(min) 
CTZAN  7.4  95.6  0.9644  0.9885  0.8811  1.07 ×  10
−4  84.3 
CTZAN  4.8  96  0.9190  0.9985  0.8145  3.24 ×  10
−4  30.4 
CTMAN  7.4  96.3  0.9369  0.9983  0.7781  4.14 ×  10
−5  233.3 
CTMAN  4.8  97.8  0.8056  0.9914  0.7106  1.65 ×  10
−4  56.8 
2.9. Cytotoxicity of CTZAN and CTMAN Nanocomposites toward Human Chang Liver Cells Line 
The possibility of toxic effect for CTZAN and CTMAN nanocomposites toward human Chang liver 
cells line was evaluated. As shown in Figure 8, no cytotoxicity effect for both nanocomposites up to 
1000  μg/mL.  In  case  of  CTZAN,  the  nanocomposite  is  slightly  more  toxic  than  the  CTMAN,  
where  the  viability  at  1000  μg/mL  for  CTZAN  and  CTMAN  nanocomposites  are  74.5  and  
91.9%, respectively. 
Figure 8. Effect of CTZAN and CTMAN nanocomposites on viability of human Chang 
liver cells line. 
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2.10. Effect of Cetirizine, CTZAN, CTMAN, Zn/Al-NO3 and Mg/Al-NO3 on Histamine Release from 
RBL2H3 Cells 
The histamine is formed from the histidine dehydroxylation, and it is stored in tissue mast cells and 
basophilic granulocytes in the blood. Histamine produces in the body in such cases, for examples; 
tissue injury and allergic reactions. Cetirizine is one of the second-generation antihistamines acting by 
displacing histamine from the H1 receptor. The increased of histamine secretion in the body may be 
responsible for several diseases, such as diarrhea, abdominal pain and cramping [29]. 
The activity of free cetirizine and intercalated cetirizine in CTZAN and CTMAN nanocomposites, 
as well as LDHs, both Zn/Al-LDH and Mg/Al-LDH are evaluated by determining their inhibitory 
potencies of histamine release into RBL2H3 cells (Figure 9). As shown in the figure, the effect of the 
components  on  histamine  release  from  RBL2H3  cell  was  increased  as  the  concentration  of  the 
components  decreased.  However,  histamine  release  reached  20,  26.5  and  54.4%  at  1000  ng/mL 
concentration for free cetirizine, CTZAN and CTMAN, respectively. due to the impact effect of zinc 
and magnesium on the histamine release [30,31], therefore, obviously Zn/Al-LDH and Mg/Al-LDH 
show different histamine release properties (Figure 9). 
The inhibition of histamine release by free cetirizine, CTZAN and CTMAN are shown in Figure 10 
and Table 5. The inhibition of histamine by the free cetirizine is higher than the intercalated cetirizine 
into CTZAN and CTMAN nanocomposites. For example, at 1000 ng/mL the free cetirizine shows 
80% inhibition compared to CTZAN and CTMAN nanocomposites which shows only 73.5% and 
45.6% inhibition, respectively. This result may be due to the small amount of cetirizine made available 
for the RBL-2H3 cells  study from  CTZAN and CTMAN nanocomposites,  due to  their controlled 
release property. The cells were treated with nanocomposites for only 10 min, and during this time, the 
release  amount  of  cetirizine  from  CTZAN  and  CTMAN  nanocomposites  was  16%  and  8.6%, 
respectively (Figure 6). Comparing this result with our previous work on intercalated cetirizine into 
zinc layered hydroxide (ZLH), the latter shows that the inhibition by the free cetirizine is less than the 
intercalated  one  [31].  Table  5  shows  that  CTZAN  has  higher  inhibition  compared  to  CTMAN 
nanocomposite. This may be due to two factors; the cumulative release of cetirizine from CTZAN is 
higher  than  that  from  CTMAN,  and  the  inhibition  by  Zn/Al-LDH  layer  is  generally  higher  
than Mg/Al-LDH. 
Table  5. Inhibition percentage of histamine release in RBL2H3 cells by the cetirizine, 
CTZAN, CTMAN, Zn/Al-LDH and Mg/Al-LDH. 
Concentration 
(ng/mL) 
Inhibition (%)   
Cetirizine  CTZAN  CTMAN  Zn/Al-LDH
  Mg/Al-LDH 
1000  80.0  73.5  45.6  3.7  2.6 
500  73.7  64.6  40.3  3.7  2.0 
250  58.1  44.0  31.7  1.4  1.5 
125  50.2  33.9  26.4  1.8  0.2 
62.5  29.0  20.1  14.2  0.7  0.2 
31.25  19.3  12.6  6.1  −1.2  0.1 
15.63  8.5  4.3  1.6  1.7  −2.9 Int. J. Mol. Sci. 2012, 13  5911 
 
 
Figure 9. Histamine release response of RBL2H3 cells treated at different concentrations 
of cetirizine, CTZAN, CTMAN, Zn/Al-LDH and Mg/Al-LDH. 
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Figure  10.  Percentage  inhibition  of  histamine  release  into  RBL2H3  cells  at  different 
concentrations of cetirizine, CTZAN, CTMAN, Zn/Al-LDH and Mg/Al-LDH. 
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3. Experimental Section  
3.1. Materials 
Cetirizine hydrochloric acid (C21H25ClN2O3· 2HCl, molecular weight 461.5, abbreviated as CT), was 
purchased  from  Upha  Pharmaceutical  Manufacturing  (Malaysia)  with  99.9%  purity  and  used  as 
received.  Other  materials  including  Zn(NO3)2· 6H2O,  Al(NO3)3· 9H2O,  Mg(NO3)2· 6H2O  sodium 
hydroxide and phosphate-buffered saline solution purchased from Sigma-Aldrich (St Louis, MO) and 
used as received. Deionized water was used in all the experiments. 
3.2. Synthesis of the Cetirizine-MgAl and Cetirizine ZnAl Nanocomposite by the Ion-Exchange Method 
The  pristine  Mg/Al-NO3  LDH  was  synthesized  by  procedure  similar  to  that  reported  
previously [32]. A solution of magnesium with 0.05 mol/L and 0.025 mol/L aluminum nitrates in 
deionized water was prepared. A solution of sodium hydroxide with 2 mol/L concentrations was added 
dropwise to Mg/Al solution with vigorous stirring under a nitrogen atmosphere until pH 10. 
Cetirizine-Mg/Al-LDH was prepared via. ion exchange process. Fresh Mg/Al-NO3 LDH precursor 
was dropped by a solution of cetirizine (0.2 mol/L) with vigorous stirring, under a nitrogen atmosphere. 
The pH mixture was 10.0 and aging for 18 h at 70 ° C and the precipitate was washed three times and 
centrifuged. The product was denoted as CTMAN. 
The cetirizine-Zn/Al- LDH was prepared via ion exchange process between the nitrate groups in the 
fresh Zn/Al-NO3 LDH with initial molar ratio, 0.1:0.025 mol/L for Zn:Al and the cetirizine anions in 
the solution (0.3 mol/L), the final pH was 7. The precipitate was aged for 18 h at 70 ° C, washed three 
times and centrifuged. The product was denoted as CTZAN. Int. J. Mol. Sci. 2012, 13  5913 
 
 
3.3. Characterization 
Powder  X-ray  diffraction  (PXRD)  patterns  were  obtained  on  a  Shimadzu  diffractometer,  
XRD-6000, using CuKα radiation at 30 KV and 30 mA, with a dwell time of 0.5 degrees per minute. 
FT-IR spectra were obtained using a Thermo Nicolet Nexus FTIR (model Smart Orbit) with 4 cm
−1 
resolution by the standard KBr disc method. Thermogravimetric and differential thermogravimetric 
analyses (TGA-DTG) were recorded on a Mettler Toledo instrument with a heating rate of 10 ° C/min 
under a nitrogen atmosphere (N2 flow rate 50 mL/min). Elemental chemical analysis for Zn, Al and 
Mg  were  carried  out  in  an  inductively  coupled  plasma  atomic  emission  spectrometry  using  a  
Perkin-Elmer spectrophotometer model Optima 2000DV (Perkin-Elmer) under standard conditions. 
Carbon,  hydrogen  and  nitrogen  were  detected  in  an  Elemental  Analyzer;  a  CHNS-932  LECO 
instrument was used. A Field Emission Scanning Electron Microscope (FESEM; NOVA NANOSEM 
230 model) was used to study the surface morphology of the samples. The controlled release study was 
accomplished using a Perkin Elmer UV-visible Spectrophotometer, Lambda 35. 
3.4. Release Study of Cetirizine from CTZAN and CTMAN Nanocomposites 
Cetirizine release profiles from the nanocomposites were determined at room temperature using 
phosphate buffered saline solution (PBS) at a concentration of 0.01 mol/L at pH 4.8 and 7.4 [5,13,33]. 
About 85 mg of each nanocomposite was added to 500 mL of the PBS media. The cumulative amount 
of cetirizine released into the solution was measured at preset time intervals at λmax = 230 nm using a 
Perkin Elmer UV-Vis spectrophotometer, model Lambda 35. 
To compare the release rate of cetirizine from CTZAN and CTMAN nanocomposites, with the 
physical mixture which contain cetirizine with Zn/Al-LDH or MgAl-LDH. About 0.62 mg of physical 
mixture was obtained by mixing 0.35 mg cetirizine with the 0.27 mg pristine Zn/Al-LDH to compare 
the release from CTZAN nanocomposite. In addition, 0.38 mg of cetirizine was mixed with 0.24 mg of 
Mg/Al-LDH was used to compare with release from CTMAN. The release of the active, cetirizine was 
determined as described above. 
3.5. Cytotoxicity Assay 
For cytotoxicity study, human Chang liver cells line were seeded into six-well plates when they 
reached 40%–60% confluence and allowed to incubate overnight at 37 ° C under a 5% CO2 atmosphere. 
After incubation for 24 h for cell attachment, the medium in the wells was then replaced with 3 mL of 
the fresh medium containing CTZAN and CTMAN nanocomposites in a concentration range of 7.8–
1000 μg/mL. A control experiment was performed without treatment by nanocomposites under the 
same conditions. After 24 h incubation, the effect of nanocomposites on cell viability was determined 
by trypan blue assay; media was aspirated off, and the cells were harvested by centrifugation then 
washed  with  cold  phosphate  buffered  saline  (to  eliminate  the  dead  cells).  Then,  
10 μL of cells was mixed with equal volume of 0.4% trypan blue (Sigma, USA) and was counted by 
using Neubauer haemocytometer (Weber, England) by clear field microscopy (Nikon, Japan). Only 
viable cells were counted. Each compound and control was assayed in triplicate.  Int. J. Mol. Sci. 2012, 13  5914 
 
 
3.6. Cell Culture Conditions and Anti IgE-Induced Histamine Release 
Rat  basophilic  leukemia  cells  RBL-2H3  are  obtained  from  American  Type  Tissue  Collection 
(ATCC; Rockville, MD). These cells are grown in Dulbecco’s Modified Eagle Medium (DMEM), 
which supplemented with 10% Fetal Bovine serum (FBS). The media contain penicillin (100 U/mL) 
and streptomycin (100 μg/ mL). Cells were grown at 37 ° C in a humidified 5% CO2 incubator. 
For the determination of histamine release, RBL-2H3 cells were plated at 1 ×  10
6 cells/well by 
addition 0.5 mL of a 2 ×  10
6 cells/mL suspension to each well of a 24-well and incubated for 18 h to 
assure  attachment  and  90%  confluence.  After  the  media  was  aspirated  off,  IgE  (0.2  μg/mL,  MP 
Biomedicals) was added in DMEM. Cells were incubated at 37 ° C for 1 h. After that, each well was 
washed  with  release  buffer  containing  1  mM  CaCl2,  40  mM  NaOH,  0.1%  BSA  119  mM  NaCl,  
5  mM  KCl,  5.6  mM  glucose,  25  mM  PIPES  and  0.4  mM  MgCl2.  The  release  buffer  containing  
Anti-IgE (1.25 μg/mL) and different concentration of cetirizine, CTZAN, CTMAN, Zn/Al-LDH and 
Mg/Al-LDH was then added to each well and cells were incubated at 37 ° C for 10 min. The amount of 
histamine release was determined using a histamine RIA kit (MP Biomedicals). 
4. Conclusions 
The intercalation of cetirizine into two types of layered double hydroxides, namely Zn/Al LDH and 
Mg/Al  LDH,  using  ion  exchange  method  to  obtain  CTZAN  and  CTMAN  nanocomposites,  was 
successfully accomplished. The XRD results confirmed the intercalation process in which cetirizine is 
arranged  between  the  interlayers  as  tilted  bilayers.  The  intercalated  amount  of  cetirizine  into  the 
CTZAN and CTMAN was estimated to be 57.2% and 60.7%, respectively. FTIR study shows that the 
bands  of  the  resulting  nanocomposites  correspond  to  the  characteristic  functional  groups  of  the 
cetirizine and LDH structures, which support the intercalation episode. Interestingly, the release rate of 
cetirizine from nanocomposites depends on the acidity of the media and type of host, where the release 
rate at pH 7.4 is remarkably lower than that at pH 4.8, and the release of cetirizine from CTMAN is 
lower  than  CTZAN.  The  inhibition  of  histamine  by  free  cetirizine  is  higher  than  the  
cetirizine-intercalated into CTZAN and CTMAN, in agreement with the sustained release properties of 
both  nanocomposites.  The  study  showed  no  cytotoxicity  effect  for  CTZAN  and  CTMAN 
nanocomposites up to 1000 μg/mL 
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